(MENAFN- GlobeNewsWire - Nasdaq) Collaborations Between Pharma Giants Boost Targeted Protein Degradation Therapies in Oncology and Chronic disease TreatmentDublin, Dec. 20, 2024 (GLOBE NEWSWIRE) -- The "Global Targeted Protein Degradation market by Type, by Application, by End-User, and by Region" report has been added to ResearchAndMarkets.com's offering. This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
The global targeted protein degradation market size was estimated to be USD 0.548 billion in 2023 and is expected to reach USD 4.37 billion by 2034 with a CAGR of 20.76% during the forecast period 2024-2034. The market will grow as a result of factors such the growing emphasis on precision medicine, rising investment in drug discovery, unmet needs in cancer and other chronic diseases, technological advancements in protein degradation platforms, collaborative efforts, and strategic partnerships.
Collaborations between biotechnology companies and pharmaceutical giants are significantly accelerating the development of target protein degradation (TPD) therapies by combining their expertise in drug discovery, clinical development, and commercialization, thereby facilitating faster market entry for innovative treatments. In March 2024, C4 Therapeutics, a biopharmaceutical company focused on small molecule drugs for targeted protein degradation, announced a strategic discovery research collaboration with Merck KGaA in Darmstadt, Germany. This partnership aims to target critical oncogenic proteins using C4T's proprietary Degronimid platform technology, advancing the development of next-generation oncology therapies.
By type, the PROTAC segment accounted for the highest revenue-grossing segment in the global targeted protein degradation market in 2023 owing to the widespread adoption of PROTACs for oncology therapies and their proven efficacy in degrading undruggable proteins. For instance, in April 2024, Novartis purchased from Vividion Therapeutics a protein degrader for prostate cancer that was ready for Phase 3. VVD-101 is the protein degrader under consideration; it is intended to specifically target the androgen receptor, a major cause of prostate cancer. The objective of Novartis is to progress this chemical towards clinical trials in order to create novel treatments for prostate cancer. Additionally, the molecular glues segment is predicted to grow at the fastest CAGR during the forecast period owing to the emergence of molecular glues as a simpler, cost-effective alternative to PROTACs and their potential to target a broader range of proteins in various diseases.
By application, the therapy development segment accounted for the highest revenue-grossing segment in the global targeted protein degradation market in 2023 owing to the increasing number of TPD-based therapeutic candidates in late-stage clinical trials, particularly in cancer and neurodegenerative diseases. For example, in March 2024, scientists from Sinai Health and the University of Toronto developed a novel platform for identifying "effector" proteins. These proteins use connections between proteins within cells to control the stability of other proteins and provide new avenues for the development of tailored therapeutics for illnesses. Additionally, the drug discovery segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing interest in TPD technologies for drug discovery, enabling the identification of novel targets and expanding therapeutic possibilities beyond conventional small molecules.
By end-user, the pharmaceutical & biotechnology companies segment accounted for the highest revenue-grossing segment in the global targeted protein degradation market in 2023 owing to the significant R&D investments and strategic collaborations for developing TPD-based therapies, driving growth in the sector. For instance, in May 2023, scientists at the Max Planck Institute of Biochemistry (MPIB) made a revolutionary finding in the field of cellular biology. They have discovered a process that makes it easier for protein modules to be recycled, which permits undesirable proteins in cells to be specifically broken down. This process is essential for guaranteeing appropriate protein turnover and preserving the integrity of the cellular supply chain. Additionally, the hospitals & clinical laboratories segment is predicted to grow at the fastest CAGR during the forecast period owing to the increased adoption of TPD therapies in clinical settings, driven by the rise in personalized medicine and the need for advanced treatment options.
North America is anticipated for the highest revenue share during the forecast period owing to the presence of leading biotechnology and pharmaceutical companies, advanced healthcare infrastructure, significant R&D investments, and the early adoption of targeted protein degradation therapies. Additionally, Asia-Pacific is expected to experience the highest compound annual growth rate (CAGR) during the forecast period, driven by the expanding biotechnology sector, increasing government initiatives to support drug development, the growth of clinical trials, and a rising demand for innovative cancer therapies in countries such as China and Japan. For instance, in May 2023, $40 million was invested in Cullgen, Inc., a biotech company with offices in Shanghai, China, and San Diego, California. Cullgen, Inc. advances small molecule therapeutics using its proprietary uSMITE technology for targeted protein degradation.
Report Scope
Base Year: 2023 Forecast Period: 2024-2034
Study Coverage
Market Forecast by Type, Application, and End-User Market Forecast for 5 Regions and 17+ Countries Exhaustive Company Profiles of the Top 10+ Major Market Players Arvinas Inc. C4 Therapeutics Inc. Kymera Therapeutics Inc. Nurix Therapeutics Inc. Bristol Myers Squibb Pfizer Inc. Amgen Inc. Novartis AG GlaxoSmithKline (GSK) plc Merck & Co. Inc. Foghorn Therapeutics Inc. AstraZeneca plc Celgene Corporation (a subsidiary of Bristol Myers Squibb) Vividion Therapeutics Inc. (acquired by Bayer) Monte Rosa Therapeutics
20% Free Customization Available to Meet Your Exact Requirements
Targeted Protein Degradation Market Analysis & Forecast by Type 2023-2034 (Revenue USD Bn)
PROTAC Molecular Glues LYTACs Others
Targeted Protein Degradation Market Analysis & Forecast by Application 2023-2034 (Revenue USD Bn)
Drug Discovery Therapy Development Cancer Neurology Infectious Diseases Cardiovascular Diseases Others
Targeted Protein Degradation Market Analysis & Forecast by End-User 2023-2034 (Revenue USD Bn)
Pharmaceutical & Biotechnology Companies Academic & Research Institutes Hospitals & Clinical Laboratories Others
Targeted Protein Degradation Market Analysis & Forecast by Region 2023-2034 (Revenue USD Bn)
North America Europe Germany France UK Spain Italy Rest of Europe
Asia-Pacific China Japan India Australia South Korea Rest of APAC
Latin America Brazil Mexico Argentina Rest of LATAM
Middle East & Africa South Africa GCC Rest of MEA
Key Attributes
| Report Attribute | Details |
| No. of Pages | 200 |
| Forecast Period | 2023-2034 |
| Estimated Market Value (USD) in 2023 | $0.55 Billion |
| Forecasted Market Value (USD) by 2034 | $4.37 Billion |
| Compound Annual Growth Rate | 20.7% |
| Regions Covered | Global |
For more information about this report visit
About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
Global Targeted Protein Degradation Market
CONTACT:
CONTACT:
Laura Wood,Senior Press Manager
...
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
MENAFN20122024004107003653ID1109016412
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.